Lilinorm

Hydrocortisone, the active ingredient in Lilinorm, is a glucocorticoid corticosteroid presented as an oral formulation for systemic use. It is employed to replace deficient cortisol in adrenal insufficiency and to reduce inflammation in various autoimmune and inflammatory conditions.

GNH USA supplies Lilinorm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable distribution across multiple regions.

Hydrocortisone is used to manage disorders that involve cortisol deficiency or excessive inflammation.

- Adrenal insufficiency: restores physiologic cortisol levels and prevents adrenal crisis. - Rheumatoid arthritis: reduces joint inflammation and pain. - Severe allergic reactions: diminishes systemic inflammatory response.

Hydrocortisone may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Increased appetite or weight gain. - Mild gastrointestinal discomfort. - Transient insomnia or mood changes. - Skin thinning or easy bruising. - Elevated blood pressure.

Serious or Rare Side Effects: - Severe hyperglycemia or new‑onset diabetes. - Opportunistic infections due to immunosuppression. - Avascular necrosis of bone. - Adrenal suppression on abrupt discontinuation. - Psychosis or severe mood disorders.

When prescribing hydrocortisone, clinicians should consider several safety measures to minimize risk.

- Dose adjustment: tailor dose to severity and patient response. - Infection risk: monitor for signs of infection due to immunosuppression. - Bone health: assess risk of osteoporosis with long‑term use. - Blood glucose: watch for hyperglycemia, especially in diabetic patients. - Store at ambient temperature: keep below 25 °C, protect from moisture and light.

Hydrocortisone can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin): may reduce hydrocortisone exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of gastrointestinal ulceration. - Diabetic agents: may require dose adjustment due to altered glucose control. - Live attenuated vaccines: possible reduced vaccine efficacy.